A Prospective Randomized Study of Ramucirumab Plus Pembrolizumab Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

The purpose of this study is to compare the drugs ramucirumab and pembrolizumab to standard of care treatment in patients whose lung cancer has progressed on immunotherapy. The study doctors hope to learn if the drug combination will help patients with stage IV or recurrent non-small cell lung cancer (NSCLC) live longer. The study is set up to find out if this drug combination is better, the same, or worse than the usual treatment. The usual approach is the care most people get for lung cancer. For patients not in a study, the usual approach is treatment with chemotherapy, which is approved by the Food and Drug Administration (FDA). Combining ramucirumab and pembrolizumab is not approved by the FDA to treat advanced lung cancer.

Are you Eligible? (Inclusion Criteria)

• Are you 18 years of age or older? Have you been diagnosed with non-small cell lung cancer (NSCLC) that has progressed to Stage IV or that has returned after treatment? Are you able to make regularly scheduled visits to the clinic for treatment and examinations?